285.60

1.43% -4.14

Ligand Pharmaceuticals Inc (LGND)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$289.74

Offen:

$287.41

24-Stunden-Volumen:

132.39K

Relative Volume:

0.38

Marktkapitalisierung:

$5.69B

Einnahmen:

$274.48M

Nettoeinkommen (Verlust:

$153.56M

KGV:

38.72

EPS:

7.3755

Netto-Cashflow:

$114.06M

1W Leistung:

+1.82%

1M Leistung:

-5.05%

6M Leistung:

+36.68%

1J Leistung:

+70.26%

1-Tages-Spanne:

$285.47

$290.00

1-Wochen-Bereich:

$275.60

$290.41

52-Wochen-Spanne:

$161.82

$326.63

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Firmenname

Ligand Pharmaceuticals Inc

Sektor

Healthcare (1074)

Branche

Biotechnology (600)

Telefon

858-550-7500

Adresse

3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA

Mitarbeiter

Twitter

@Ligand_LGND

Nächster Verdiensttermin

2026-08-06

Neueste SEC-Einreichungen

LGND's Discussions on Twitter

Compare LGND vs VRTX, REGN, ARGX, MRNA, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
LGND Ligand Pharmaceuticals Inc	285.60	5.73B	274.48M	153.56M	114.06M	7.3755
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-11	Eingeleitet	BofA Securities	Buy
2025-12-09	Eingeleitet	Citigroup	Buy
2025-04-10	Eingeleitet	Stifel	Buy
2024-10-03	Eingeleitet	Oppenheimer	Outperform
2024-07-30	Eingeleitet	RBC Capital Mkts	Outperform
2021-04-14	Fortgesetzt	Stephens	Overweight
2021-02-04	Bestätigt	H.C. Wainwright	Buy
2020-10-06	Eingeleitet	Barclays	Overweight
2020-03-24	Herabstufung	Argus	Buy → Hold
2020-03-10	Eingeleitet	Guggenheim	Neutral
2020-02-06	Eingeleitet	The Benchmark Company	Buy
2019-09-19	Hochstufung	Barclays	Equal Weight → Overweight
2019-06-11	Eingeleitet	Barclays	Equal Weight
2019-05-03	Bestätigt	H.C. Wainwright	Buy
2019-03-06	Bestätigt	H.C. Wainwright	Buy
2018-10-29	Hochstufung	ROTH Capital	Neutral → Buy
2018-10-02	Bestätigt	H.C. Wainwright	Buy
2018-09-11	Bestätigt	Argus	Buy
2018-08-17	Eingeleitet	Goldman	Neutral
2018-08-08	Herabstufung	ROTH Capital	Buy → Neutral
2018-06-21	Eingeleitet	Argus	Buy
2017-12-27	Bestätigt	H.C. Wainwright	Buy
2017-09-05	Fortgesetzt	H.C. Wainwright	Buy
2016-10-05	Bestätigt	H.C. Wainwright	Buy
2016-08-05	Herabstufung	Deutsche Bank	Hold → Sell
2016-03-11	Eingeleitet	Sidoti	Buy
2016-03-03	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten

Aug 21, 2026

$100 Invested In Ligand Pharmaceuticals 10 Years Ago Would Be Worth This Much Today - Benzinga

Aug 21, 2026

Aug 20, 2026

LGND6487833 Bond Yield and Price — FINRA:LGND6487833 - TradingView

Aug 20, 2026

Aug 19, 2026

Enterprise value to revenue forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView

Aug 19, 2026

Ligand (LGND) Q2 2026 Earnings Call Transcript - AOL.com

Aug 19, 2026

TVTX, LGND Stocks In Spotlight Ahead Of Monday’s FDA Call On Kidney Drug Filspari - Stocktwits

Aug 19, 2026

Aug 16, 2026

Bank of America Corp DE Raises Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat

Aug 16, 2026

LGND6487833 Bond Profile — Key Metrics - TradingView

Aug 16, 2026

Aug 15, 2026

Ligand Pharmaceuticals(LGND.US) Officer Sells US$9.24 Million in Common Stock - Moomoo

Aug 15, 2026

Aug 14, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) Director Jason Haas Sells 7,138 Shares - MarketBeat

Aug 14, 2026

Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells 31,641 Shares of Stock - MarketBeat

Aug 14, 2026

Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares - Investing.com South Africa

Aug 14, 2026

Ligand Pharmaceuticals CFO Octavio Espinoza sells $9.2m in shares By Investing.com - Investing.com UK

Aug 14, 2026

Ligand Pharmaceuticals (LGND) director exercises options and sells 7,138 shares - Stock Titan

Aug 14, 2026

LGND Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus

Aug 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

Aug 14, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Leerink Partners - MarketBeat

Aug 14, 2026

Stifel reiterates Buy on Ligand Pharma stock, $332 target By Investing.com - Investing.com Canada

Aug 14, 2026

Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run - Yahoo Finance

Aug 14, 2026

LGND|Ligand Pharmaceuticals Inc|Price:294.595|Chg%:+5.775 - TradingKey

Aug 14, 2026

Aug 13, 2026

Ligand Pharmaceuticals (LGND) Reaffirms 2026 Guidance, Is The Stock Fully Priced? - Yahoo Finance

Aug 13, 2026

Invesco Ltd. (LGND holder) reports 6.1% beneficial stake in Ligand Pharmaceuticals - Stock Titan

Aug 13, 2026

Aug 12, 2026

Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance

Aug 12, 2026

Enterprise value to EBIT forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView

Aug 12, 2026

LIGAND PHARMACEUTICALS INC SEC Filing (Aug 12, 2026) - Stock Titan

Aug 12, 2026

Ligand (NASDAQ: LGND) holder Jason Haas files Form 144 for stock sale - Stock Titan

Aug 12, 2026

Citi Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $390 - Moomoo

Aug 12, 2026

Aug 11, 2026

Q1 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

Aug 11, 2026

Q4 2025 Ligand Pharmaceuticals Inc Earnings Call Transcript - GuruFocus

Aug 11, 2026

Ligand Pharmaceuticals Incorporated (LGND) stock price, news, quote and history - Yahoo Finance UK

Aug 11, 2026

Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News, Quote & History - Yahoo! Finance Canada

Aug 11, 2026

Ligand Pharmaceuticals (LGND) Short Interest & Short Float | Updated Aug 2026 - MarketBeat

Aug 11, 2026

Aug 10, 2026

LGND: XOMA Acquisition Closed - Smartkarma

Aug 10, 2026

Weekly Recap: Q2 revenue, royalty growth and $700M convertible notes - TradingView

Aug 10, 2026

Aug 09, 2026

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Aug 09, 2026

Aug 08, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) Issues Quarterly Earnings Results - MarketBeat

Aug 08, 2026

A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $326 to $370 - moomoo.com

Aug 08, 2026

California State Teachers Retirement System Acquires 4,987 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat

Aug 08, 2026

LGND SWOT Analysis: Strong Revenue Growth Amidst Valuation Conce - GuruFocus

Aug 08, 2026

Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $370 - Moomoo

Aug 08, 2026

Aug 07, 2026

RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $345 - Moomoo

Aug 07, 2026

Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $326 - Moomoo

Aug 07, 2026

Ligand Pharmaceuticals (LGND) Releases Q2 2026 Earnings: Revenue Declines but EPS Jumps - Quiver Quantitative

Aug 07, 2026

LGND Maintained by RBC Capital -- Price Target Raised to $345 - GuruFocus

Aug 07, 2026

Ligand Pharmaceuticals 2Q 2026: Revenue $63.69M, EPS $2.22— 10-Q Summary - TradingView

Aug 07, 2026

Ligand Pharmaceuticals (NASDAQ: LGND) lifts Q2 net income to 48,508 - Stock Titan

Aug 07, 2026

Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat

Aug 07, 2026

Ligand Pharmaceuticals, Inc. : H.c. Wainwrigh - moomoo.com

Aug 07, 2026

RBC Adjusts PT on Ligand Pharmaceuticals to $345 From $340, Maintains Outperform Rating - marketscreener.com

Aug 07, 2026

Aug 06, 2026

LIGAND PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $358 FROM $289 - Bitget

Aug 06, 2026